Parkinson’s Disease Studies

2023

  • Guttuso T, Jr., Shepherd R, Frick L, Feltri ML, Frerichs V, Ramanathan M, Zivadinov R, Bergsland N. Lithium’s effects on therapeutic targets and MRI biomarkers in Parkinson’s disease: a pilot clinical trial. IBRO Neurosci Rep 2023:7;14:429-434. [Open Article]

2022

  • Guttuso T, Sirica D, Tosun D, Zivadinov R, Pasternak O, Weintraub D, Baglio F, Bergsland N (2022). Thalamic dorsomedial nucleus free water correlates with cognitive decline in Parkinson’s disease. Mov Dis;37(3):490-501. [Open article]

2020

  • Jakimovski D, Bergsland N, Dwyer MG, et al. Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls. Neurobiol Aging 2020;90:84-92. [Open article]

2019

  • Bergsland N, Zivadinov R, Schweser F, Hagemeier J, Lichter D and Guttuso T, Jr. (2019). "Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease." Mov Disord 34(7): 1006-1013. [Open article]
  • Bergsland N, Tavazzi E, Schweser F, Jakimovski D, Hagemeier J, Dwyer MG and Zivadinov R (2019). "Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders." CNS Drugs 33(11): 1073-1086. [Open article]

2018

  • Guttuso T, Jr., Bergsland N, Hagemeier J, Lichter DG, Pasternak O and Zivadinov R (2018). "Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease." AJNR Am J Neuroradiol 39(3): 479-484. [Open article]

2016

  • Gupta S, Zivadinov R, Ramanathan M and Weinstock-Guttman B (2016). "Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?" Expert Rev Neurother: 1-11. [Open article]

2015

  • Mak E, Dwyer MG, Ramasamy DP, Au WL, Tan LC, Zivadinov R and Kandiah N (2015). "White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease." J Neuroimaging 25(5): 754-760. [Open article]

2014

  • Mak E, Bergsland N, Dwyer MG, Zivadinov R and Kandiah N (2014). "Subcortical atrophy is associated with cognitive impairment in mild Parkinson disease: a combined investigation of volumetric changes, cortical thickness, and vertex-based shape analysis." AJNR Am J Neuroradiol 35(12): 2257-2264. [Open article]

2013

  • Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF, Dalaker TO, Beyer MK, Aarsland D, Andreasson U, Lange J, Tysnes OB, Zivadinov R and Larsen JP (2013). "Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease." J Neurol Neurosurg Psychiatry 84(5): 537-543. [Open article]

2012

  • Hagemeier J, Geurts JJ and Zivadinov R (2012). "Brain iron accumulation in aging and neurodegenerative disorders." Expert Rev Neurother 12(12): 1467-1480. [Open article]

2011

  • Dalaker TO, Zivadinov R, Ramasamy DP, Beyer MK, Alves G, Bronnick KS, Tysnes OB, Aarsland D and Larsen JP (2011). "Ventricular enlargement and mild cognitive impairment in early Parkinson's disease." Mov Disord 26(2): 297-301. [Open article]

2010

  • Dalaker TO, Zivadinov R, Larsen JP, Beyer MK, Cox JL, Alves G, Bronnick K, Tysnes OB, Antulov R, Dwyer MG and Aarsland D (2010). "Gray matter correlations of cognition in incident Parkinson's disease." Mov Disord 25(5): 629-633. [Open article]

2009

  • Dalaker TO, Larsen JP, Bergsland N, Beyer MK, Alves G, Dwyer MG, Tysnes OB, Benedict RH, Kelemen A, Bronnick K and Zivadinov R (2009). "Brain atrophy and white matter hyperintensities in early Parkinson's disease(a)." Mov Disord 24(15): 2233-2241. [Open article]
  • Dalaker TO, Larsen JP, Dwyer MG, Aarsland D, Beyer MK, Alves G, Bronnick K, Tysnes OB and Zivadinov R (2009). "White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease." Neuroimage 47(4): 2083-2089. [Open article]

2002

  • Zorzon M, Capus L, Pellegrino A, Cazzato G and Zivadinov R (2002). "Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy." Acta Neurol Scand 105(2): 77-82. [Open article]